MedTrace Logo

Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients

NCT00255918 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-07-01

No results posted yet for this study

Summary

This study will determine the effectiveness of a drug, dimethoxbenzylidene anabaseine, in producing beneficial effects similar to that of nicotine in individuals with schizophrenia.

Conditions

Interventions

DRUG

Dimethoxybenzylidene anabaseine (DMXB-A)

DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose

DRUG

Placebo

Placebo dosed to match active medication

DRUG

Dimethoxybenzylidene anabaseine (DMXB-A)

DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Robert Freedman, MD · University of Colorado, Denver

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00255918 on ClinicalTrials.gov